Key result
Senolytic therapy with dasatinib and quercetin cuts AF inducibility ~100% in post-MI rats.
Why the study?
Cellular senescence is believed to contribute to many cardiac conditions, but its role in AF remains unknown.
Does senolytic therapy with dasatinib and quercetin reduce atrial fibrillation susceptibility in rat models of myocardial infarction?
Does senolytic therapy with dasatinib and quercetin reduce atrial fibrillation susceptibility in rat models of myocardial infarction?
Absolute Event Rate: 0% vs 89%
p-value: p=<0.001
Senolytic therapy with dasatinib and quercetin significantly reduces atrial fibrillation inducibility and atrial fibrosis in a rat model of myocardial infarction, suggesting cellular senescence plays a key role in AF pathophysiology.
No takes yet. Share an insight, caveat, or question.
Senolytics warrant no clinical use for post-MI AF; leaves open senescence as a therapeutic target in humans.
Mehdizadeh et al. (2024) studied Atrial fibrillation. Dasatinib and quercetin (D+Q) vs. Vehicle was evaluated on Atrial fibrillation inducibility in myocardial infarction rats (p=<0.001). Senolytic therapy with dasatinib and quercetin reduced atrial fibrillation inducibility in myocardial infarction rats from 89% to 0% (P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: